{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bay C"],"funding":["Deutsche Forschungsgemeinschaft","Faculty of Medicine of Heidelberg University"],"pagination":["3637"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8998838"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["23(7)"],"pubmed_abstract":["The solute carrier L-type amino acid transporter 1 (LAT-1/SLC7A5) is a viable target for drug delivery to the central nervous system (CNS) and tumors due to its high abundance at the blood-brain barrier and in tumor tissue. LAT-1 is only localized on the cell surface as a heterodimer with CD98, which is not required for transporter function. To support future CNS drug-delivery development based on LAT-1 targeting, we established an ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) assay for stable isotopically labeled leucine ([<sup>13</sup>C<sub>6</sub>, <sup>15</sup>N]-L-leucine), with a dynamic range of 0.1-1000 ng/mL that can be applied for the functional testing of LAT-1 activity when combined with specific inhibitors and, consequently, the LAT-1 inhibition"],"journal":["International journal of molecular sciences"],"pubmed_title":["Functional Characterization of the Solute Carrier LAT-1 (SLC7A5/SLC2A3) in Human Brain Capillary Endothelial Cells with Rapid UPLC-MS/MS Quantification of Intracellular Isotopically Labelled L-Leucine."],"pmcid":["PMC8998838"],"funding_grant_id":["SFB 1389","Physician Scientist Program"],"pubmed_authors":["Weiss J","Sauter M","Bay C","Haefeli WE","Bajraktari-Sylejmani G","Burhenne J"],"additional_accession":[]},"is_claimable":false,"name":"Functional Characterization of the Solute Carrier LAT-1 (SLC7A5/SLC2A3) in Human Brain Capillary Endothelial Cells with Rapid UPLC-MS/MS Quantification of Intracellular Isotopically Labelled L-Leucine.","description":"The solute carrier L-type amino acid transporter 1 (LAT-1/SLC7A5) is a viable target for drug delivery to the central nervous system (CNS) and tumors due to its high abundance at the blood-brain barrier and in tumor tissue. LAT-1 is only localized on the cell surface as a heterodimer with CD98, which is not required for transporter function. To support future CNS drug-delivery development based on LAT-1 targeting, we established an ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) assay for stable isotopically labeled leucine ([<sup>13</sup>C<sub>6</sub>, <sup>15</sup>N]-L-leucine), with a dynamic range of 0.1-1000 ng/mL that can be applied for the functional testing of LAT-1 activity when combined with specific inhibitors and, consequently, the LAT-1 inhibition","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2025-04-04T09:53:22.056Z","creation":"2024-11-14T23:48:30.243Z"},"accession":"S-EPMC8998838","cross_references":{"pubmed":["35408997"],"doi":["10.3390/ijms23073637"]}}